Research
Hormonal
Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.
Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.
StrongSupportsmedium confidence
It is also found that dual gastric inhibitory polypeptide (GIP)/GLP-1 agonists is regarded as the more effective in treating obesity than the GLP-1 agonist alone.
Why this rating
Based on published clinical data from various clinical trials.
Source
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Nidhi Sharma et al. · Journal of Diabetology · 2023
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →